Daniel Roshammar
Overview
Explore the profile of Daniel Roshammar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eckernas E, Koomen J, Timmermann C, Carhart-Harris R, Roshammar D, Ashton M
CPT Pharmacometrics Syst Pharmacol
. 2023 Sep;
12(10):1398-1410.
PMID: 37675853
N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed...
2.
Eckernas E, Timmermann C, Carhart-Harris R, Roshammar D, Ashton M
CPT Pharmacometrics Syst Pharmacol
. 2023 Feb;
12(4):474-486.
PMID: 36762714
N,N-dimethyltryptamine (DMT) is a psychedelic substance and is being used as a research tool in investigations of the neurobiology behind the human consciousness using different brain imaging techniques. The effects...
3.
Eckernas E, Timmermann C, Carhart-Harris R, Roshammar D, Ashton M
Clin Transl Sci
. 2022 Sep;
15(12):2928-2937.
PMID: 36088656
N,N-dimethyltryptamine (DMT) is a psychedelic compound that is believed to have potential as a therapeutic option in several psychiatric disorders. The number of clinical investigations with DMT is increasing. However,...
4.
Mitchell L, Roshammar D, Huang F, Albisetti M, Brandao L, Bomgaars L, et al.
Thromb Haemost
. 2022 Aug;
122(9):1573-1583.
PMID: 35909257
Background: Dabigatran etexilate, a direct oral thrombin inhibitor, is approved to treat venous thromboembolism (VTE) in both adults and children. Objectives: This population analysis characterized relationships between dabigatran total plasma...
5.
Roshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, et al.
J Thromb Haemost
. 2021 Feb;
19(5):1259-1270.
PMID: 33636042
Background: Dabigatran etexilate (DE), a direct oral thrombin inhibitor, has been evaluated in children with venous thromboembolism (VTE) using oral solution, pellets, or capsules. Objectives: This study evaluated DE pharmacokinetics...
6.
Astrand M, Amilon C, Roshammar D, Himmelmann A, Angiolillo D, Storey R, et al.
Br J Clin Pharmacol
. 2018 Nov;
85(2):413-421.
PMID: 30414387
Aims: To characterize ticagrelor exposure-response relationship for platelet inhibition in patients with stable coronary artery disease (CAD) and a history of myocardial infarction (MI), using nonlinear mixed effects modelling and...
7.
Aoki Y, Roshammar D, Hamren B, Hooker A
J Pharmacokinet Pharmacodyn
. 2017 Nov;
44(6):581-597.
PMID: 29103208
Population model-based (pharmacometric) approaches are widely used for the analyses of phase IIb clinical trial data to increase the accuracy of the dose selection for phase III clinical trials. On...
8.
Roshammar D, Bergstrand M, Andersson T, Storey R, Hamren B
Int J Clin Pharmacol Ther
. 2017 Feb;
55(5):416-424.
PMID: 28139972
Objective: The population pharmacokinetics of ticagrelor and its active metabolite AR-C124910XX were characterized following ticagrelor 60 mg or 90 mg twice daily oral long-term treatment in 4,426 patients with a...
9.
Roshammar D, Nyberg J, Andersson T, Stanski D, Storey R, Hamren B
J Clin Pharmacol
. 2016 Nov;
57(5):573-583.
PMID: 27859337
The relationships between drug exposure and the composite risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke as well as the risk of TIMI major bleeding were estimated following...
10.
Rose T, Roshammar D, Erichsen L, Grundemar L, Ottesen J
Drugs R D
. 2016 May;
16(2):165-72.
PMID: 27139012
Objective: The aim of this study was to characterise the population pharmacokinetics of FE 999049, a novel recombinant human follicle-stimulating hormone (FSH), after multiple dosing in healthy women, taking into...